scholarly journals Age as an Independent Factor in the Permanent Chemotherapy-Induced Amenorrhea Incidence in Breast Cancer Patients at Dr. Moewardi Hospital, Surakarta, Indonesia

2021 ◽  
Vol 9 (B) ◽  
pp. 816-820
Author(s):  
Mudib Mudib ◽  
Kristanto Yuli Yarso ◽  
Henky Agung Nugroho
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Risk Factor ◽  
Cancer Patients ◽  
The Other ◽  
Common Side Effect ◽  
Breast Cancer Patients ◽  
Chi Square ◽  
Premenopausal Breast Cancer ◽  
Exact Test

Background: Chemotherapy Induced Amenorrhea (CIA) is one common side effect of chemotherapy in breast cancer patients. Some who have CIA may experience menstruation return while others experience permanent CIA. Aim: to examines the factors that contribute to the incidence of persistent CIA in breast cancer patients. Methods: The population of this retrospective study was new breast cancer patients with premenopausal status when they started receiving chemotherapy at dr Moewardi Hospital Surakarta, Indonesia, from January 2019 to July 2021. To determine the relationship, the chi-square/Fisher’s exact test was performed. Risk factor analysis on the incidence of permanent CIA was carried out by using a bivariate logistic regression test, followed by multivariate analysis. Results: A number of 105 premenopausal breast cancer patients who received chemotherapy were found. Of these patients, 97 (93.38%) patients experienced CIA and 8 patients (6.62%) continued to menstruate. Of all the subjects having CIA, 49 patients (46.67%) menstruated again while the other 48 (45.71%) had persistent CIA.  Age factor has a significant relationship with the incidence of permanent CIA (p =< 0.001), where patients aged > 45 years tend to have permanent CIA incidence with a proportion of 42 patients (87.5%) (p < 0.05). The multivariate analysis showed that age > 45 years (OR = 75.117; 95% CI = 12.671-445.311; p = < 0.001) was the most dominant risk factor associated with the incidence of permanent CIA, while other variables as risk factors for permanent CIA based on multivariate analysis were Stage III (R = 6.677; 95% CI = 1.370-32,545; p = 0.019) compared to stages I and II, and BMI in the normal category (OR = 5.485; 95% CI = 1.083-27.786; p = 0.040) compared to excess BMI. The other variables were not found to be associated with the incidence of permanent CIA. Conclusion: Age is a major factor associated with permanent CIA incidence. Other factors related to this study are staging and BMI.   Keywords: Age, Permanent, Chemotherapy Induced Amenorrhea, Breast Cancer

scholarly journals Abnormalities by pulmonary regions studied with computer tomography and clinical correlation following local-regional radiotherapy for breast cancer

2013 ◽  
Vol 02 (01) ◽  
pp. 021-025 ◽  
Author(s):  
Kallol Bhadra ◽  
Niladri B. Patra ◽  
Amitabha Manna ◽  
Kabasi Apurba ◽  
Jayanta Pal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Computer Tomography ◽  
Classification System ◽  
Pulmonary Complications ◽  
Breast Cancer Patients ◽  
Chi Square ◽  
Exact Test ◽  
The Mean

Abstract Background: Adjuvant local-regional radiotherapy (RT) is commonly recommended for breast cancer patients. Postoperative adjuvant RT for breast cancer is associated with pulmonary side effects. This study was undertaken to measure the RT-induced pulmonary radiological changes with computer tomography (CT) scan using a CT-adapted modification of the Arriagada classification system, and to correlate these changes to RT techniques, pulmonary complications, and pulmonary function. The aim of the study is to study pulmonary radiological abnormalities with CT following different RT techniques for breast cancer, and their correlation to pulmonary complications and reduction in forced vital capacity (FVC). Materials and Methods: CT scans of the lungs were performed prior to and 4 months following RT in 53 breast cancer patients treated with local-regional RT. The radiological abnormalities were analyzed with a CT-adapted modification of a classification system originally proposed by Arriagada. The patients were monitored for RT-induced pulmonary complications. FVC was measured prior to and 6 months following RT. Statistical analysis used were that increasing CT scores were correlated with pulmonary complications ( P < 0.001). The correlation between density grade (0-3, 4-9) and pulmonary complications (no complication vs slight/severe) was tested using Chi-square exact test for trend (2-sided). In addition, correlation between CT scores and FVC was done. Results: Increasing CT scores were correlated with pulmonary complications ( P < 0.001). The mean reduction of FVC for patients scoring 4-9 (-220 ml) was larger than for patients scoring 0-3 (-15 ml) (Spearson correlation coefficient significant at 0.01 level 2 tailed). But the mean reduction of FVC with greater volume of lung irradiated was not statistically different than lesser volume of lung irradiated ( P > 0.05). Conclusion: Radiological abnormalities detected on CT images and scored with a modification of Arriagada′s classification system can be used as an objective endpoint for pulmonary side effects in postmastectomy RT.

scholarly journals Molecular study of BRCA-1,2 and P53 gene polymorphisms among post-operative breast cancer patients

2019 ◽  
Vol 10 (4) ◽  
pp. 3570-3577
Author(s):  
Aws Rassul hussain Al-salin ◽  
Hammadi Al-Hilaly ◽  
Rawaa Magid
Keyword(s):  
Breast Cancer ◽  
Risk Factor ◽  
Cancer Patients ◽  
P53 Gene ◽  
Molecular Study ◽  
The Other ◽  
Breast Cancer Patients ◽  
Body Regions ◽  
Other Hand ◽  
And Control

Breast cancer is a malignant tumor in groups of cancer cells that may develop into (invade) or spread to distant body regions around tissues. In both advanced and developing nations and in many parts of the globe, the burden of breast cancer is rising. It's the most prevalent malicious person illness in females, with 18% of all female cancers and the third most prevalent cause of cancer death globally.  This case-control study was organized to explore the potential role of chosen genetic parameters in the Al-Diwanyia province in random samples of breast cancer patients the research, 5 ml of blood samples from 50 women with post-operative breast cancer attending the outpatient oncology department at Al Diwaniyia Teaching Hospital were employed compared to 50 women without cancer, patient ages and control ranged from 18 to 80 years. Among the three susceptibility genes studied, BRCA In BRCA-1 GG genotype evidently proposed a risk factor for tumor as had an (OR 5.3191) and risk factor (EF 0.065); AG & AA genotypes, on the other hand, played a rather preventive part as they had no risk factor (PF) of 0.0476 & 0.1667 respectively and low OR (0.7619 & 0.7917 respectively) and patients had 16%, and 84% of patients had G and A alleles respectively. The genotype of BRCA-2 AG As had the risk factor (OR 13.4146) and the risk factor (EF 0.1851), the AA genotype, on the other hand, did not have a risk factor role since it had a protective fraction (PF) of 0.9103 and a low OR (0.0731). Patients have 10% of G and 90% of A alleles compared to 100% of A only. In the P53 CC genotype, tumor etiology has evidently been proposed, as was the case with (OR 1.2941) and risk factor (EF 0.091). The GC genotype, on the other hand, did not have a risk factor as it had (PF) of 0.087 and low OR (0.4565) and patients had 56 percent of G allele and 44 percent of C allele compared to 52 percent of G and 48 percent of C control.

Hair Loss Prevention by a Scalp Cooling Device in Early Breast Cancer Patients: The Poliambulanza Preliminary Experience

2019 ◽  
Vol 14 (1) ◽  
pp. 66-71 ◽  
Author(s):  
Tiziana Prochilo ◽  
Alessandra Huscher ◽  
Federica Andreis ◽  
Mara Mirandola ◽  
Elisabetta Zaina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hair Loss ◽  
Depression Scale ◽  
Hair Follicles ◽  
Common Side Effect ◽  
Scalp Cooling ◽  
Breast Cancer Patients ◽  
Cooling Device ◽  
End Of Treatment

Background: The most effective agents in the treatment of breast cancer have a common side effect, the hair loss. Some studies reported a reduction of hair loss with the use of the scalp cooling device. Indeed, it decreases the drug accumulation in the hair follicles. We report our preliminary experience with a scalp cooling device in reducing chemotherapy-induced alopecia and related distress in breast cancer patients undergoing adjuvant chemotherapy. </P><P> Methods: Hair loss grading and treatment tolerability were evaluated during chemotherapy every 21 days and 3 weeks after the last cycle of chemotherapy via Dean’s scale by patients and operators and a comfort analogic scale by patients. We administered the Hospital Anxiety and Depression Scale questionnaire at the baseline and at the end of treatment to assess the distress related to chemotherapy- induced alopecia. Results: Among the 46 patients identified, 27 accepted the device. The eligible chemotherapy regimens included docetaxel+cyclophosphamide (TC), doxorubicin+cyclophosphamide (AC) and paclitaxel (P) weekly+trastuzumab (T). 24 pts (89%) completed the treatment; 3 pts (11%) treated with AC prematurely interrupted use of the scalp-cooling device due to inefficacy. After the last cycle of chemotherapy, the number of patient who perceived a HL < grade 2 was 16 (59%). The hair retention reported by operators has been higher (78%). 81.5% of patients well tolerated the treatment. Conclusion: In our study, the scalp-cooling device reduced chemotherapy-induced alopecia in taxane- based chemotherapy. Furthermore, it suggests a discordance in hair loss perception between patients and operators.

scholarly journals Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer

2021 ◽  
Author(s):  
Ming-Feng Hou ◽  
Fu Ou-Yang ◽  
Chung-Liang Li ◽  
Fang-Ming Chen ◽  
Chieh-Han Chuang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gut Microbiota ◽  
Cancer Patients ◽  
Critical Role ◽  
Postmenopausal Breast Cancer ◽  
Diagnostic Value ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Α Diversity ◽  
Functional Pathways

AbstractIn Western countries, breast cancer tends to occur in older postmenopausal women. However, in Asian countries, the proportion of younger premenopausal breast cancer patients is increasing. Increasing evidence suggests that the gut microbiota plays a critical role in breast cancer. However, studies on the gut microbiota in the context of breast cancer have mainly focused on postmenopausal breast cancer. Little is known about the gut microbiota in the context of premenopausal breast cancer. This study aimed to comprehensively explore the gut microbial profiles, diagnostic value, and functional pathways in premenopausal breast cancer patients. Here, we analyzed 267 breast cancer patients with different menopausal statuses and age-matched female controls. The α-diversity was significantly reduced in premenopausal breast cancer patients, and the β-diversity differed significantly between breast cancer patients and controls. By performing multiple analyses and classification, 14 microbial markers were identified in the different menopausal statuses of breast cancer. Bacteroides fragilis was specifically found in young women of premenopausal statuses and Klebsiella pneumoniae in older women of postmenopausal statuses. In addition, menopausal-specific microbial markers could exhibit excellent discriminatory ability in distinguishing breast cancer patients from controls. Finally, the functional pathways differed between breast cancer patients and controls. Our findings provide the first evidence that the gut microbiota in premenopausal breast cancer patients differs from that in postmenopausal breast cancer patients and shed light on menopausal-specific microbial markers for diagnosis and investigation, ultimately providing a noninvasive approach for breast cancer detection and a novel strategy for preventing premenopausal breast cancer.

A validated model to predict low recurrence risk distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer patients.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 532-532
Author(s):  
Yasue Tsuchida ◽  
Sachiko Ohde ◽  
Ryota Nakamura ◽  
Yoko Kanada ◽  
Sakiko Miura ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Prediction Model ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Hormone Receptor ◽  
Recurrence Score ◽  
Premenopausal Women ◽  
Breast Cancer Patients ◽  
Derivation Cohort

532 Background: In the prospective TAILORx and RxPONDER trials, the 21-gene Recurrence Score (RS) showed endocrine therapy alone was non-inferior to chemo-endocrine therapy in the analysis of invasive disease-free survival in postmenopausal hormone-receptor (HR)-positive breast cancer patients with RS < = 25. They also indicated chemotherapy was associated with benefit for women 50 years or younger with RS 11 to 25. However, in Japan, the test is not conventionally available because of non-coverage by national insurance. We aimed to develop and validate a model to predict RS using clinicopathological factors that identify patients who would have low risk shown by testing the 21-gene RS and can avoid chemotherapy. Methods: Four hundred patients, including 187 N0/1 postmenopausal, and 213 N0 premenopausal women who underwent surgery and had the RS from St. Luke’s International Hospital, Tokyo, Japan, were included in derivation cohort. Derivation cohort was divided into 2 groups by RS 25; patients with RS of 0 to 25 (n = 321) and with RS over 26 (n = 79). Multivariate logistic regression analysis was performed using candidate factors for all patients and pre- or postmenopausal patients. The prediction model was validated using an external cohort of 70 patients from Showa University School of Medicine, Tokyo, Japan. Results: Nuclear grade (NG) (adjusted OR, 5.28, 95% CI, 2.47–11.30), high Progesterone receptor (PgR) expression (Allred score 7-8) (adjusted OR, 10.62, 95% CI, 5.34–21.13) and low Ki67 level ( < = 20%) (adjusted OR, 5.29, 95% CI, 2.33-12.01) were significant independent predictors of RS of 0 to 25. With these factors could predict RS of 0 to 25 (AUC of 0.848, 95% CI, 0.803-0.893) with the highest probability of low-RS for 100%. The prediction model of the validation cohort had same discriminatory ability having an AUC of 0.812 (95% CI, 0.701-0.923). In postmenopausal patients, NG (adjusted OR, 4.81, 95% CI, 1.72–13.42), high PgR expression (adjusted OR, 10.62, 95% CI, 4.52–37.72), and low Ki67 level (adjusted OR, 4.94, 95%CI, 1.87-13.04) were significantly associated with RS of 0 to 25 in multivariate analysis. A regression model with these 4 factors could predict RS of 0 to 25 (AUC of 0.842, 95%CI, 0.782-0.902). In premenopausal patients, NG (adjusted OR, 8.76, 95% CI, 1.14–67.40), high PgR expression (adjusted OR, 3.22, 95% CI, 1.61–6.43), and low Ki67 level (adjusted OR, 2.87, 95% CI, 1.20–6.87) were significantly associated with RS of 0 to 10 in multivariate analysis. These factors could predict RS of 0 to 10 (AUC of 0.811, 95% CI, 0.731-0.891). However, the highest probability of low-RS provided this model for premenopausal women was 46.8%. Conclusions: Our validated model could provide useful information to distinguish low-RS especially for postmenopausal patients with high reproducibility. However, for premenopausal women, the 21-gene RS is warranted.

COVID-related anxiety is prevalent and accurately reflects serious COVID risks in breast cancer patients.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 12053-12053
Author(s):  
Marisa C. Weiss ◽  
Stephanie Kjelstrom ◽  
Meghan Buckley ◽  
Adam Leitenberger ◽  
Melissa Jenkins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
P Value ◽  
Breast Cancer Patients ◽  
Chi Square ◽  
Liver And Kidney ◽  
Chi Square Test ◽  
A Current

12053 Background: A current cancer diagnosis is a risk factor for serious COVID-19 complications (CDC). In addition, the pandemic has caused major disruptions in medical care and support networks, resulting in treatment delays, limited access to doctors, worsening health disparities, social isolation; and driving higher utilization of telemedicine and online resources. Breastcancer.org has experienced a sustained surge of new and repeat users seeking urgent information and support. To better understand these unmet needs, we conducted a survey of the Breastcancer.org Community. Methods: Members of the Breastcancer.org Community were invited to complete a survey on the effects of the COVID-19 pandemic on their breast cancer care, including questions on demographics, comorbidities (including lung, heart, liver and kidney disease, asthma, diabetes, obesity, and other chronic health conditions); care delays, anxiety due to COVID-related care delays, use of telemedicine, and satisfaction with care during COVID. The survey was conducted between 4/27/2020-6/1/2020 using Survey Monkey. Results were tabulated and compared by chi square test. A p-value of 0.05 is considered significant. Data were analyzed using Stata 16.0 (Stata Corp., Inc, College Station, TX). Results: Our analysis included 568 breast cancer patients of whom 44% had ≥1 other comorbidities associated with serious COVID-19 complications (per CDC) and 37% had moderate to extreme anxiety about contracting COVID. This anxiety increased with the number of comorbidities (p=0.021), age (p=0.040), and with a current breast cancer diagnosis (p=0.011) (see table). Anxiety was significantly higher in those currently diagnosed, ≥65, or with ≥3 other comorbidities, compared to those diagnosed in the past, age <44, or without other comorbidities. Conclusions: Our survey reveals that COVID-related anxiety is prevalent at any age regardless of overall health status, but it increased with the number of other comorbidities, older age, and a current breast cancer diagnosis. Thus, reported anxiety is proportional to the risk of developing serious complications from COVID. Current breast cancer patients of all ages—especially with other comorbidities—require emotional support, safe access to their providers, and prioritization for vaccination.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document